Displaying 397 - 408 of 452
Liver Tumours
5

Bristol-Myers Squibb: Evolving Treatment Landscape of HCC - Digital ILC 2020

View
Liver Tumours
5

Bristol-Myers Squibb: Evolving Treatment Landscape of HCC - Digital ILC 2020

View
Liver Tumours
5

Bristol-Myers Squibb: Evolving Treatment Landscape of HCC - Digital ILC 2020

View
Liver Tumours
5

Bristol-Myers Squibb: Evolving Treatment Landscape of HCC - Digital ILC 2020

View
Cirrhosis & Complications
6

Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019

View
Cirrhosis & Complications
6

Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019

View
Cirrhosis & Complications
6

Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019

View
Cirrhosis & Complications
6

Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019

View
Cirrhosis & Complications
6

Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019

View
Cirrhosis & Complications
6

Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019

View
General Hepatology
6

Alexion: My Patient Care vs Restricted Access to Medicines - The International Liver Congress™ 2019

View
General Hepatology
6

Alexion: My Patient Care vs Restricted Access to Medicines - The International Liver Congress™ 2019

View